Immunocore Holdings plc SEC filings IMCR
Immunocore Holdings plc has 279 filings in SEC EDGAR's recent list, going back to Apr 13, 2016. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 14, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 27, 2026 | May 27, 2026 |
| S-8 | Employee stock plan registration | May 8, 2026 | — |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 16, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Apr 16, 2026 | May 27, 2026 |
| 8-K |
Current report
Results of operations
|
Feb 25, 2026 | Feb 25, 2026 |
| 10-K | Annual report | Feb 25, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Jan 30, 2026 | Jan 27, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Jan 9, 2026 | Jan 9, 2026 |
| 8-K |
Current report
Officer or director change
|
Nov 28, 2025 | Nov 26, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 15, 2025 | May 15, 2025 |
| S-8 | Employee stock plan registration | May 7, 2025 | — |
| 8-K |
Current report
Results of operations
|
May 7, 2025 | May 7, 2025 |
| 10-Q | Quarterly report | May 7, 2025 | Mar 31, 2025 |
| ARS | Annual report to shareholders | Apr 4, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Apr 4, 2025 | May 15, 2025 |
| PRE 14A | Preliminary proxy statement | Mar 24, 2025 | May 15, 2025 |
| 8-K |
Current report
Other events
|
Mar 17, 2025 | Mar 17, 2025 |
| 424B7 | 427b7 | Mar 17, 2025 | — |
| POSASR | Filing | Mar 17, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 10, 2025 | Mar 10, 2025 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Feb 26, 2025 | Feb 25, 2025 |
| 10-K | Annual report | Feb 26, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Jan 10, 2025 | Jan 10, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 2, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Agreement ended
|
Nov 8, 2024 | Nov 8, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2024 | Nov 6, 2024 |
| 10-Q | Quarterly report | Nov 6, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Other events
|
Sep 16, 2024 | Sep 14, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 29, 2024 | Aug 28, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
May 31, 2024 | May 31, 2024 |
| 8-K |
Current report
Other events
|
May 30, 2024 | May 29, 2024 |
| 8-K |
Current report
Material agreement, Officer or director change
|
May 28, 2024 | May 28, 2024 |
| 8-K |
Current report
Shareholder vote results
|
May 23, 2024 | May 23, 2024 |
| 8-K |
Current report
Results of operations
|
May 8, 2024 | May 8, 2024 |
| 10-Q | Quarterly report | May 8, 2024 | Mar 31, 2024 |
| ARS | Annual report to shareholders | Apr 12, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Apr 12, 2024 | May 23, 2024 |
| 8-K |
Current report
Other events
|
Apr 5, 2024 | Apr 5, 2024 |
| 424B7 | Filing | Apr 5, 2024 | — |
| PRE 14A | Preliminary proxy statement | Apr 2, 2024 | May 23, 2024 |
| S-8 | Employee stock plan registration | Mar 21, 2024 | — |
| S-3ASR | Automatic shelf registration | Mar 21, 2024 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Feb 28, 2024 | Feb 28, 2024 |
| 10-K | Annual report | Feb 28, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Feb 2, 2024 | Jan 30, 2024 |
| 8-K |
Current report
Results of operations, Other events
|
Jan 29, 2024 | Jan 29, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Jan 5, 2024 | Jan 5, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 2, 2024 | Jan 2, 2024 |
| 6-K | Current report (foreign issuer) | Nov 7, 2023 | Nov 7, 2023 |
| 6-K | Current report (foreign issuer) | Aug 10, 2023 | Jun 30, 2023 |
| 6-K | Current report (foreign issuer) | Jul 14, 2023 | Jul 14, 2023 |
| 6-K | Current report (foreign issuer) | Jun 5, 2023 | Jun 5, 2023 |
| 6-K | Current report (foreign issuer) | May 16, 2023 | May 16, 2023 |
| 6-K | Current report (foreign issuer) | May 10, 2023 | May 10, 2023 |
| 6-K | Current report (foreign issuer) | Apr 18, 2023 | Apr 18, 2023 |
| 6-K | Current report (foreign issuer) | Apr 18, 2023 | Apr 18, 2023 |
| S-8 | Employee stock plan registration | Apr 6, 2023 | — |
| 6-K | Current report (foreign issuer) | Mar 10, 2023 | Mar 10, 2023 |
| 6-K | Current report (foreign issuer) | Mar 2, 2023 | Mar 2, 2023 |
| 20-F | Annual report (foreign issuer) | Mar 1, 2023 | Dec 31, 2022 |
| 6-K | Current report (foreign issuer) | Mar 1, 2023 | Mar 1, 2023 |
| 6-K | Current report (foreign issuer) | Feb 22, 2023 | Feb 22, 2023 |
| 6-K | Current report (foreign issuer) | Jan 11, 2023 | Jan 11, 2023 |
| 6-K | Current report (foreign issuer) | Jan 9, 2023 | Jan 9, 2023 |
| 6-K | Current report (foreign issuer) | Dec 8, 2022 | Dec 8, 2022 |
| 6-K | Current report (foreign issuer) | Dec 2, 2022 | Dec 2, 2022 |
| 6-K/A | Filing | Nov 18, 2022 | Sep 30, 2022 |
| 6-K | Current report (foreign issuer) | Nov 14, 2022 | Nov 14, 2022 |
| 6-K | Current report (foreign issuer) | Nov 9, 2022 | Nov 9, 2022 |
| 6-K | Current report (foreign issuer) | Sep 30, 2022 | Sep 30, 2022 |
| 424B7 | Filing | Sep 30, 2022 | — |
| 6-K | Current report (foreign issuer) | Sep 9, 2022 | Sep 9, 2022 |
| 424B5 | Prospectus supplement | Sep 9, 2022 | — |
| 6-K | Current report (foreign issuer) | Sep 9, 2022 | Sep 9, 2022 |
| 6-K | Current report (foreign issuer) | Aug 10, 2022 | Aug 9, 2022 |
| D | Filing | Jul 28, 2022 | — |
| 6-K | Current report (foreign issuer) | Jul 20, 2022 | Jul 20, 2022 |
| 6-K | Current report (foreign issuer) | Jul 11, 2022 | Jul 11, 2022 |
| 6-K | Current report (foreign issuer) | Jun 27, 2022 | Jun 27, 2022 |
| 6-K | Current report (foreign issuer) | Jun 9, 2022 | Jun 9, 2022 |
| 6-K | Current report (foreign issuer) | Jun 8, 2022 | Jun 8, 2022 |
| 6-K | Current report (foreign issuer) | Jun 6, 2022 | Jun 6, 2022 |
| 6-K | Current report (foreign issuer) | Jun 3, 2022 | Jun 3, 2022 |
| S-8 | Employee stock plan registration | May 17, 2022 | — |
| 6-K | Current report (foreign issuer) | May 12, 2022 | May 12, 2022 |
| 6-K | Current report (foreign issuer) | May 11, 2022 | May 11, 2022 |
| 424B7 | Filing | May 5, 2022 | — |
| 6-K | Current report (foreign issuer) | Apr 14, 2022 | Apr 14, 2022 |
| F-3ASR | Filing | Apr 4, 2022 | — |
| 6-K | Current report (foreign issuer) | Apr 4, 2022 | Apr 4, 2022 |
| 20-F | Annual report (foreign issuer) | Mar 3, 2022 | Dec 31, 2021 |
| 6-K | Current report (foreign issuer) | Mar 3, 2022 | Mar 3, 2022 |
| 6-K | Current report (foreign issuer) | Jan 26, 2022 | Jan 26, 2022 |
| 6-K | Current report (foreign issuer) | Dec 7, 2021 | Dec 7, 2021 |
| 6-K | Current report (foreign issuer) | Nov 10, 2021 | Nov 10, 2021 |
| 6-K | Current report (foreign issuer) | Aug 24, 2021 | Aug 24, 2021 |
| 6-K | Current report (foreign issuer) | Aug 11, 2021 | Aug 11, 2021 |
| 6-K | Current report (foreign issuer) | May 12, 2021 | Mar 31, 2021 |
| S-8 | Employee stock plan registration | Apr 12, 2021 | — |
| 20-F | Annual report (foreign issuer) | Mar 25, 2021 | Dec 31, 2020 |
| SEC STAFF LETTER | Filing | Feb 9, 2021 | — |
| 424B4 | Prospectus | Feb 8, 2021 | — |
| EFFECT | Filing | Feb 4, 2021 | — |
| EFFECT | Filing | Feb 4, 2021 | — |
| F-1MEF | Filing | Feb 4, 2021 | — |
| CERT | Filing | Feb 4, 2021 | — |
| CERT | Filing | Feb 4, 2021 | — |
| CORRESP | Letter to the SEC | Feb 3, 2021 | — |
| F-1/A | Filing | Feb 3, 2021 | — |
| F-6/A | Filing | Feb 2, 2021 | — |
| CORRESP | Letter to the SEC | Feb 2, 2021 | — |
| CORRESP | Letter to the SEC | Feb 2, 2021 | — |
| 8-A12B | Filing | Feb 2, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 2, 2021 | — |
| SEC STAFF LETTER | Filing | Feb 1, 2021 | — |
| CORRESP | Letter to the SEC | Feb 1, 2021 | — |
| F-1/A | Filing | Feb 1, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 29, 2021 | — |
| F-6 | Filing | Jan 27, 2021 | — |
| CORRESP | Letter to the SEC | Jan 21, 2021 | — |
| CORRESP | Letter to the SEC | Jan 15, 2021 | — |
| F-1 | Registration statement (foreign issuer) | Jan 15, 2021 | — |
| SEC STAFF LETTER | Filing | Dec 30, 2020 | — |
| DRS/A | Filing | Dec 22, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 14, 2020 | — |
| DRS/A | Filing | Nov 19, 2020 | — |
| DRS | Filing | Nov 17, 2020 | — |
Showing 138 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IMCR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Oxfordshire, United Kingdom
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1671927
- Former names
- Immunocore Ltd (until Feb 1, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.